Skip to content
DataLookout
Menu

NCT06139666

The Effect of Liposomal Bupivacaine Nerve Block (Exparel) in Rotator Cuff Surgery

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Sponsor changed: The Cooper Health System to Cooper Norcross Health Show 6 more changesShow less
    • Study completion date changed from estimate of Jun 1, 2025 to Dec 24, 2025
    • Eligibility criteria expanded, about 7 words
    • Trial status changed: Unknown → Completed
    • Final enrollment: 128 participants (planned 160)
    • Secondary endpoints: details revised at 1 of 1 entry
    • Publications: details revised at 5 of 6 entries
  2. Minor Changed Registry marked status Unknown; last known: Enrolling by Invitation
  3. Minor Trial status: Enrolling by Invitation to Unknownv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Use of pain medications
Timeframe: 2 week postoperative visit

Secondary (1)

Pain severity

Arms and interventions

Control- Bupivacaine AloneActive comparator

patients will receive a standard interscalene block with bupivacaine alone (25 cc of bupivacaine)

Study- ExparelExperimental

patients will receive an interscalene block with Exparel solution, which is an extended-release formulation of bupivacaine consisting of 10cc liposomal bupivacaine mixed with 15cc bupivacaine. This is approved and used at the study institution

Drugs: Exparel Injectable Solution, Bupivacaine Injectable Solution

Sites

1 site in 1 country

  • Cooper University HospitalCamden, New Jersey, United States